List of Excipients in Branded Drug SULFACETAMIDE

Generic Drugs Containing SULFACETAMIDE

Company	Ingredient	NDC	Excipient
Pacific Pharma Inc	sulfacetamide sodium	60758-018	BENZALKONIUM CHLORIDE
Pacific Pharma Inc	sulfacetamide sodium	60758-018	EDETATE DISODIUM
Pacific Pharma Inc	sulfacetamide sodium	60758-018	HYDROCHLORIC ACID
Pacific Pharma Inc	sulfacetamide sodium	60758-018	POLYSORBATE 80
Pacific Pharma Inc	sulfacetamide sodium	60758-018	POLYVINYL ALCOHOL
Pacific Pharma Inc	sulfacetamide sodium	60758-018	SODIUM HYDROXIDE
Pacific Pharma Inc	sulfacetamide sodium	60758-018	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS

What are the Most Frequently-Used Excipients in SULFACETAMIDE?

# Of NDCs	Excipient
1	BENZALKONIUM CHLORIDE
1	EDETATE DISODIUM
1	HYDROCHLORIC ACID
1	POLYSORBATE 80
1	POLYVINYL ALCOHOL
1	SODIUM HYDROXIDE
1	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS

Sulfacetamide Excipient Strategy and Commercial Opportunities

Last updated: August 20, 2026

Sulfacetamide is a mature, low-cost antibacterial with limited active-ingredient patent protection and substantial formulation differentiation potential. The strongest commercial opportunities are in sodium sulfacetamide dermatology products, sulfur combinations, preservative-sensitive ophthalmic products, and differentiated dosage forms with improved tolerability, stability, packaging, or patient convenience. Broad generic competition limits pricing power, while excipient and delivery-system patents can support narrower market positions.

What products contain sulfacetamide?

Sulfacetamide is marketed primarily as sulfacetamide sodium, the water-soluble sodium salt used in ophthalmic and dermatologic products.

Product category	Typical strength	Common dosage forms	Primary use
Ophthalmic sulfacetamide sodium	10%	Solution, suspension, ointment	Bacterial conjunctivitis and other susceptible ocular infections
Dermatologic sulfacetamide sodium	10%	Lotion, cream, cleanser, gel, foam	Acne vulgaris, seborrheic dermatitis, rosacea
Sulfacetamide sodium and sulfur	10% / 5%	Cleanser, suspension, cream, lotion, foam	Acne, rosacea, seborrheic dermatitis
Sulfacetamide sodium ophthalmic ointment	Commonly 10%	Ointment	Ocular infection where longer residence time is desirable

FDA labeling identifies sulfacetamide sodium as a sulfonamide antibacterial. Dermatologic labels commonly combine it with sulfur, which provides keratolytic activity and supports use in acne, rosacea, and seborrheic dermatitis [1-4].

The active ingredient is old and chemically straightforward. Commercial value therefore depends more on formulation execution, product availability, prescriber familiarity, and channel access than on molecular innovation.

What excipients are used in sulfacetamide formulations?

Excipient selection depends on the route, concentration, pH target, preservative system, viscosity, and packaging format.

Ophthalmic solutions

Sulfacetamide sodium ophthalmic solutions generally require:

• Purified or sterile water as the vehicle
• pH adjustment with buffers or alkalizing agents
• Sodium chloride or another tonicity modifier
• A preservative for multidose containers
• Chelating or stabilizing excipients where justified by compatibility data
• Low-extractables, sterile packaging components

Sulfacetamide sodium is highly water soluble, which supports solution products. The central formulation challenge is balancing solubility, ocular comfort, chemical stability, preservative efficacy, and microbial protection after opening.

A commercial developer should screen:

1. pH-related degradation and color change.
2. Preservative efficacy across the labeled in-use period.
3. Ocular irritation from preservatives and buffer concentration.
4. Container-closure adsorption and extractables.
5. Compatibility with low-density polyethylene, polypropylene, or ophthalmic dropper systems.
6. Drop size consistency and residual volume.

Benzalkonium chloride has historically been used in ophthalmic products, but chronic exposure can create tolerability concerns. A preservative-free unit-dose product could target patients requiring repeated dosing, contact-lens users after appropriate labeling restrictions, and prescribers seeking lower preservative exposure. The tradeoff is higher packaging cost, more complex filling, and reduced convenience compared with multidose bottles.

Ophthalmic suspensions and ointments

Suspensions may use suspending agents, wetting agents, viscosity modifiers, and structured vehicles. Ointments use petrolatum, mineral oil, or related ophthalmic-grade hydrocarbon bases.

These formats can create differentiated product profiles:

• Suspensions can increase residence time but require shake instructions and dose uniformity controls.
• Ointments can prolong contact time but may blur vision and reduce patient acceptance.
• Gelling drops can improve retention while preserving a drop format.
• Unit-dose systems can reduce preservative exposure and contamination risk.

The main technical barrier is not active dissolution. It is maintaining dose uniformity, sterility, physical stability, and acceptable patient handling.

Dermatologic solutions, lotions, and cleansers

Topical dermatology products use excipients such as:

• Water or hydroalcoholic vehicles
• Humectants including glycerin or propylene glycol
• Emollients and skin-conditioning agents
• Surfactants in cleansers
• Carbomers, cellulose derivatives, or other rheology modifiers
• pH adjusters
• Preservatives
• Fragrance-free masking systems where needed

Sulfacetamide-containing dermatology products can be irritating or drying, particularly when combined with sulfur, alcohol, surfactants, or aggressive preservatives. An excipient strategy focused on barrier preservation can differentiate a product more effectively than a simple concentration change.

Potential improvements include:

• Lower-irritancy preservative systems
• Reduced alcohol content
• Fragrance-free formulations
• Noncomedogenic emollients
• Humectant-balanced vehicles
• Foam or pump delivery that limits hand contact
• Controlled-release or film-forming vehicles
• Wash-off products with optimized contact time

Sulfacetamide sodium and sulfur products

Sulfacetamide-sulfur combinations provide the clearest formulation opportunity because the two actives have different physicochemical behavior. Sulfur is poorly water soluble and can create odor, sedimentation, grittiness, discoloration, and container compatibility problems.

Important excipient functions include:

• Wetting and dispersion of sulfur particles
• Suspension stabilization
• Odor masking
• Reduction of sedimentation and caking
• Controlled foaming in cleansers
• Skin moisturization
• Improved wash-off behavior
• Preservation across a heterogeneous system

A high-value formulation target is a sulfur product with low odor, uniform dosing, rapid rinseability, and lower dryness. That profile could support a branded generic or dermatology-focused private-label product even when the underlying active ingredients are unprotected.

What patents protect sulfacetamide products?

Sulfacetamide has no meaningful remaining basic-compound patent barrier. The active ingredient and conventional dosage forms have been used for decades. Any commercial patent risk is more likely to arise from product-specific formulation, delivery, packaging, or method-of-use claims than from the sulfacetamide molecule itself.

IP category	Likely status for sulfacetamide	Commercial implication
Basic sulfacetamide compound	Expired or historically unprotected	No durable molecule-level exclusivity
Sodium salt and conventional solutions	Mature technology	Broad generic competition
Ophthalmic preservative systems	Potentially patentable if technically distinct	Narrow formulation protection possible
Sulfur suspension systems	Potential formulation value	Potential differentiation around stability, odor, and texture
Foam, gel, and controlled-release vehicles	Patentable in specific implementations	Product-specific barriers may arise
Container-closure and delivery systems	Potentially protectable	Device or combination claims may support a premium product
Acne, rosacea, or seborrheic dermatitis methods	Often vulnerable to prior art and obviousness attacks	Limited value unless tied to a distinct regimen or formulation

The FDA Orange Book should be reviewed by product number and dosage form because listed patents can differ between ophthalmic and dermatologic products [5]. A generic applicant must assess both listed patents and non-Orange-Book risks, including formulation patents, device patents, trade secrets, and state-law issues.

A new sulfacetamide product should not rely on an assumption that the old active ingredient is unpatentable. The relevant freedom-to-operate question concerns the exact formulation, excipient combination, delivery device, manufacturing process, and labeled use.

When does sulfacetamide lose exclusivity?

Sulfacetamide lost practical molecule-level exclusivity long ago. The current market is dominated by abbreviated new drug application pathways, legacy prescription products, and authorized or private-label generic supply.

Exclusivity type	Sulfacetamide position
New chemical entity exclusivity	Not commercially relevant
Orphan-drug exclusivity	Not relevant to established sulfacetamide indications
Pediatric exclusivity	Not a meaningful current barrier
Basic active-ingredient patents	Historically expired or unavailable
Formulation patents	Product-specific and potentially relevant
Method-of-use patents	Usually narrow and vulnerable to invalidity or design-around
Generic entry	Generally feasible where an approved reference product exists

No biosimilar pathway applies. Sulfacetamide is a small-molecule drug, so competing products proceed through generic drug pathways rather than abbreviated biologics license applications.

What is the FDA regulatory status of sulfacetamide?

Sulfacetamide products are generally prescription drugs. FDA-approved labeling covers ophthalmic and dermatologic products, including combination products with sulfur [1-4].

Regulatory considerations include:

• ANDA suitability for products with the same active ingredient, strength, dosage form, route, and comparable quality attributes.
• Demonstration of pharmaceutical equivalence and bioequivalence where applicable.
• Sterility and preservative-effectiveness requirements for ophthalmic products.
• Microbial limits and preservative control for dermatologic products.
• In vitro release testing for certain topical products.
• Comparative physical characterization for suspensions, foams, and semisolids.
• Labeling consistency with the reference product.

Topical semisolid products can require more than a simple qualitative and quantitative sameness analysis. Critical quality attributes may include droplet or particle size, viscosity, pH, globule size, emulsion structure, rheology, spreadability, and in vitro release performance.

What formulations are protected by sulfacetamide patents?

The most defensible patent opportunities are formulation-specific.

Low-irritancy ophthalmic formulation

Potential claim themes include:

• Preservative-free multidose packaging
• A defined buffer system with improved stability
• Reduced benzalkonium chloride exposure
• A low-blur ointment or gel
• A drop-size-controlled delivery system
• Improved chemical stability under accelerated storage

The patent must establish a technical effect, such as improved stability, lower irritation, reduced degradation, or more consistent dosing. Merely substituting one conventional buffer or preservative for another may face obviousness challenges.

Sulfur suspension formulation

Potential claim themes include:

• Narrow sulfur particle-size distribution
• Improved suspension stability
• Low-odor sulfur dispersion
• Reduced staining or discoloration
• A defined surfactant and rheology-modifier system
• Controlled release from a leave-on vehicle
• Improved wash-off and reduced skin dryness

The strongest filings would link the excipient system to measured performance rather than claim a broad list of conventional ingredients.

Foam and pump delivery

Foam products can support claims covering:

• Foam density
• Collapse time
• Dose delivered per actuation
• Active uniformity
• Propellant or foaming system
• Container-closure configuration
• Reduced contamination during use

Device and formulation claims should be coordinated. A formulation patent alone may be easier to design around if a competitor can use a different pump or foam architecture.

How strong is the sulfacetamide patent estate?

The estate is weak at the active-ingredient level and potentially moderate in narrow formulation segments.

Factor	Assessment
Molecular protection	Very weak
Conventional solution protection	Weak
Ophthalmic device differentiation	Moderate if supported by issued claims
Sulfur suspension differentiation	Moderate
Foam delivery	Moderate to potentially strong for a specific platform
Manufacturing know-how	Moderate where particle engineering or aseptic processing is complex
Regulatory switching costs	Low to moderate
Generic price protection	Low
Brand loyalty in dermatology	Moderate for established prescriber and patient segments

Patent strength should be judged claim by claim. A patent covering a specific sulfur particle-size range, excipient ratio, or device configuration may have commercial value, but it will not prevent all sulfacetamide competition.

Which companies are competing in sulfacetamide?

The market includes branded dermatology companies, generic manufacturers, contract manufacturers, and pharmacy-label suppliers. Products have historically been associated with companies such as Almirall, Bausch Health and its dermatology affiliates, Taro Pharmaceutical Industries, Padagis, Perrigo, Akorn, and other generic or specialty suppliers, depending on product, market, and availability.

Commercial competition is fragmented because:

• Product availability changes by manufacturer.
• Some legacy products are discontinued or intermittently supplied.
• Dermatology products may be distributed through specialty channels.
• Ophthalmic products compete on supply reliability and formulary access.
• Sulfur combinations have differentiated sensory profiles that influence prescribing.

A market entrant should distinguish between approved product holders, current commercial suppliers, discontinued label holders, and contract manufacturers. FDA Drugs@FDA and the Orange Book provide the relevant approval and patent records, while DailyMed provides current labeling and inactive-ingredient information [1, 5, 6].

What generic entry risks exist for sulfacetamide?

Generic entry risk is high for conventional products and lower for technically differentiated products.

High-risk segments

• Standard 10% ophthalmic solutions
• Conventional ophthalmic ointments
• Basic 10% dermatologic lotions
• Simple sulfacetamide-sulfur creams or cleansers

These products have mature technology, established manufacturing processes, and limited room for premium pricing.

Lower-risk segments

• Preservative-free ophthalmic products
• Stable multidose preservative-reduced systems
• Low-odor sulfur foams
• Barrier-compatible leave-on dermatology vehicles
• Products with superior pump delivery
• Pediatric or sensitive-skin positioning, where supported by labeling
• Reliable supply in categories with intermittent shortages

The main launch risk is not patent litigation. It is low net pricing, pharmacy substitution, limited reimbursement differentiation, and the cost of maintaining a small-volume product.

What patent litigation affects sulfacetamide?

Sulfacetamide is not associated with the level of ongoing patent litigation seen in high-value branded drugs such as GLP-1 agonists, oncology products, or biologics. The principal legal risks are likely to involve:

• Product-specific formulation patents
• Orange Book-listed patents for a particular reference product
• ANDA Paragraph IV certifications
• Trade dress and trademark disputes
• Manufacturing quality or supply disputes
• Licensing restrictions for branded dermatology products

A Paragraph IV challenge would be product-specific. It would not challenge sulfacetamide as a whole. The applicant would need to identify the reference product, listed patents, and the proposed formulation or labeling position.

Settlement agreements are also likely to be product-specific and commercially limited. A settlement involving one sulfacetamide formulation would not establish a general market-entry date for all sulfacetamide products.

What licensing deals are available for sulfacetamide?

Licensing opportunities are more likely to involve commercial infrastructure than active-ingredient rights. Potential deal structures include:

• Acquisition or in-license of an approved ANDA
• Regional commercialization rights
• Supply agreements with dermatology-focused manufacturers
• Private-label arrangements for cleansers or foams
• Co-development of preservative-free ophthalmic products
• Licensing of pump, foam, or container technology
• Contract manufacturing with minimum-volume commitments

The most attractive asset may be an approved but supply-constrained product with a validated manufacturing process. An acquirer should review approval history, manufacturing-site status, product discontinuation records, warning letters, recalls, and historical shortage data before assigning value.

How can companies create commercial opportunities with excipients?

A practical strategy is to separate products into three tiers.

Tier	Product concept	Commercial objective
Tier 1	Standard generic solution or lotion	Low-cost market entry and supply participation
Tier 2	Improved sulfur cleanser, foam, or sensitive-skin lotion	Premium generic or dermatology channel differentiation
Tier 3	Preservative-free ophthalmic or advanced delivery system	Higher technical barrier and potential formulation IP

The best near-term opportunity is usually a dermatology product with improved sensory performance. Patients often discontinue topical therapy because of dryness, odor, stinging, residue, or poor cosmetic acceptability. Excipients can address those issues without changing the active ingredient or strength.

The highest technical opportunity is a preservative-free or preservative-reduced ophthalmic product. That segment requires more expensive development, sterile manufacturing, package testing, and regulatory work, but it offers greater differentiation than a conventional topical lotion.

How does sulfacetamide compare with competing dermatology products?

Attribute	Sulfacetamide sodium	Benzoyl peroxide	Azelaic acid	Metronidazole	Sulfur
Main positioning	Antibacterial and anti-inflammatory dermatology therapy	Acne antibacterial and keratolytic	Acne and rosacea	Rosacea	Keratolytic and antimicrobial
Formulation challenge	Irritation, preservative compatibility	Oxidation and bleaching	Solubility and texture	Stability and vehicle acceptability	Odor, sedimentation, staining
Patent maturity	Very mature	Mature	Mature	Mature	Mature
Differentiation potential	Vehicle and combination products	Delivery and irritation control	Texture and tolerability	Gel, cream, and foam systems	Odor and sensory profile
Generic pressure	High	High	High	High	High

Sulfacetamide has the strongest commercial rationale when paired with a formulation advantage or sulfur combination. It is less attractive as an undifferentiated conventional generic.

Key Takeaways

• Sulfacetamide is a mature small-molecule drug with no meaningful basic active-ingredient exclusivity.
• Sodium sulfacetamide is used mainly in ophthalmic and dermatologic products.
• The most important excipient challenges are pH control, preservative tolerability, sulfur suspension stability, odor, viscosity, and packaging compatibility.
• Conventional 10% solutions and lotions face high generic competition and limited pricing power.
• Preservative-free ophthalmic products, low-irritancy dermatology vehicles, sulfur foams, and low-odor cleansers offer the clearest differentiation.
• Formulation, device, and manufacturing patents may create narrow protection, but they will not recreate molecule-level exclusivity.
• There is no biosimilar pathway for sulfacetamide.
• Paragraph IV risk must be evaluated against the specific reference product and its Orange Book listings.
• Licensing value is more likely to reside in approved ANDAs, reliable manufacturing, supply-constrained products, or delivery technology than in sulfacetamide itself.
• A commercially viable launch requires low manufacturing cost, reliable supply, strong sensory performance, and a clear channel strategy.

FAQs

Can sulfacetamide be reformulated as an over-the-counter product?

Sulfacetamide dermatology products are generally prescription products. An OTC conversion would require an FDA-supported regulatory pathway, appropriate labeling, and a monograph or approved application basis. Reformulation alone would not create OTC status.

Is sulfacetamide suitable for a preservative-free eye drop?

Yes, sulfacetamide sodium is water soluble and technically suitable for a preservative-free ophthalmic solution. The commercial product would require unit-dose packaging or a validated multidose preservative-free container, along with sterility and in-use stability data.

Can sulfur particle size be patented in a sulfacetamide cleanser?

Potentially. A claim directed to a defined particle-size distribution may be patentable if it produces a demonstrated technical benefit, such as improved suspension stability, reduced odor, lower grittiness, or better dose uniformity.

Does a sulfacetamide generic need clinical trials?

Usually, an ANDA relies on pharmaceutical equivalence, bioequivalence, quality data, and other FDA requirements rather than full clinical efficacy trials. The evidence package depends on the dosage form, route, reference product, and FDA guidance.

What is the most attractive sulfacetamide product opportunity?

A low-irritancy sulfacetamide sodium and sulfur foam or cleanser is often the most practical opportunity because it can use established actives while differentiating through odor control, suspension stability, skin feel, packaging, and adherence-oriented design.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: Sulfacetamide sodium ophthalmic solution labeling. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). DailyMed: Sulfacetamide sodium topical products labeling. National Library of Medicine.
3. U.S. Food and Drug Administration. (n.d.). DailyMed: Sulfacetamide sodium and sulfur topical products labeling. National Library of Medicine.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drug products. https://www.accessdata.fda.gov/scripts/cder/daf/
5. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
6. National Library of Medicine. (n.d.). DailyMed: Current medication labeling. https://dailymed.nlm.nih.gov/ dailymed/